MOSCOW (MRC) -- Evonik Industries has started basic engineering for the construction of a second world-scale production plant for the amino acid DL-methionine in Singapore, said the company on its site.
The plant complex, with a projected annual production capacity of 150,000 metric tons, is expected to come on stream in 2019. The Evonik committees have now approved the basic engineering.
The new complex will be erected next to Evonik’s existing methionine plant on Jurong Island, Singapore, which was commissioned in late 2014. "Like our first methionine plant in Singapore, which went on stream on schedule, this project too is progressing according to plan," explains Reiner Beste, chairman of the Board of the Management of Evonik Nutrition & Care GmbH.
Singapore was once again selected as the site because Evonik can service the Asian growth market particularly well from there. And once again, in the new, fully backward-integrated production complex, Evonik will produce all strategically important precursors itself. "This guarantees high product quality as well as supply security," says Beste.
The specialty chemicals group is already producing DL-methionine at world-scale plants in Antwerp (Belgium), Wesseling/Cologne (Germany), Mobile (Alabama, USA), and Singapore.
As MRC informed earlier, Evonik Industries acquired the company MedPalett AS, with headquarters in Sandnes (Norway), on March 3, 2016. MedPalett AS specializes in food ingredients containing anthocyanins.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world.
MRC